Potential Benefit of Metformin as Treatment for Colon Cancer: the Evidence so Far |
Abdelsatir, Azza Ali
(Histocenter)
Husain, Nazik Elmalaika (Department of Pathology, Faculty of Medicine and Health Sciences, Omdurman Islamic University) Hassan, Abdallah Tarig (Department of Pharmacy, Blue Nile Pharmaceuticals) Elmadhoun, Wadie M (Nile Valley University) Almobarak, Ahmed O (Department of Pathology, Faculty of Medicine, University of Medical Sciences and Technology) Ahmed, Mohamed H (Department of Medicine, Milton Keynes University Hospital NHS Foundation Trust) |
1 | Aleksandrova K, Boeing H, Jenab M, et al (2011). Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res, 4, 1873-83. DOI |
2 | Buzzai M, Jones R, Amaravadi R, et al (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 67, 6745-52. DOI |
3 | Cho Y, Ko B, Kim S, et al (2014). Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res, 12, 139-45. DOI |
4 | Donohoe C, O'farrell N, Doyle S, Reynolds J (2014). The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol, 7, 38-50. DOI |
5 | Giovannucci E, Pollak M, Platz E, et al (2000). A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev, 9, 345-9. |
6 | Grimberg A & Cohen P (2000). Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol, 183, 1-9. DOI |
7 | Handelsman Y, Leroith D, Bloomgarden Z, et al (2013). Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract, 19, 675-93. DOI |
8 | Higurashi T, Takahashi H, Endo H, et al (2012). Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer, 12, 118. DOI |
9 | Hillon P, Guiu B, Vincent J, Petit J (2010). Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol Clin Biol, 34, 529-33. DOI |
10 | Hsu Y, Chiu H, Liou J, et al (2012). Glycated hemoglobin A1c is superior to fasting plasma glucose as an independent risk factor for colorectal neoplasia. Cancer Causes Control, 23, 321-8. DOI |
11 | Sanchez N, Stierman B, Saab S, et al (2012). Physical activity reduces risk for colon polyps in a multiethnic colorectal cancer screening population. BMC Res Notes, 5, 312. DOI |
12 | Sandhu M, Dunger D, Giovannucci E (2002). Insulin, insulinlike growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst, 94, 972-80. DOI |
13 | Saydah SH, Platz EA, Rifai N, et al (2003). Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev, 12, 412-8. |
14 | Schoenalgire C, Amrein L, Zakikhani M, Panasci L & Pollak M (2010). Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer, 17, 351-60. DOI |
15 | Spillane S, Bennett K, Sharp L, Barron T (2014). Metformin exposure and disseminated disease in patients with colorectal cancer. Cancer Epidemiol, 38, 79-84. DOI |
16 | Sui X, Xu Y, Yang J, et al (2014). Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. PLoS One, 9, 97781. DOI |
17 | Trevisan M, Liu J, Muti P, et al (2001). Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev, 10, 937-41. |
18 | Tsilidis K, Capothanassi D, Allen N, et al (2014). Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-totreat trial. Diabetes Care, 37, 2522-32. DOI |
19 | Huang HE, Yang YC, Wu JS, et al (2014). The relationship between different glycemic statuses and colon polyps in a Taiwanese population. J Gastroenterol, 49, 1145-51. DOI |
20 | Inoue M, Tsugane S (2012). Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer, 19, F1-8. DOI |
21 | Jenkins P (2004). Acromegaly and cancer. Horm Res, 62, 108-15. DOI |
22 | Kalaany N, Sabatini D (2009). Tumours with PI3K activation are resistant to dietary restriction. Nature, 458, 725-31. DOI |
23 | Kanadiya M, Gohel T, Sanaka M, Thota P, Shubrook J (2013). Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complications, 27, 463-6. DOI |
24 | Kaneko R, Nakazaki N, Tagawa T, et al (2014) A new index of abdominal obesity which effectively predicts risk of colon tumor development in female Japanese. Asian Pac J Cancer Prev, 15, 1005-10. DOI |
25 | Khaw K, Wareham N, Bingham S, et al (2004). Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev, 13, 915-9. |
26 | Kim D (2012). [Obesity and gastrointestinal cancer-related factor]. Korean J Gastroenterol, 59, 8-15. DOI |
27 | Larsson S, Wolk A (2007). Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr, 86, 556-65. DOI |
28 | Lee D, Kim B, Lee J, et al (2012). The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes. Korean J Gastroenterol, 60, 355-61. DOI |
29 | Wang X, Zhang Y (2014). Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol, 20, 4178-88. DOI |
30 | Vu HT, Ufere N, Yan Y, et al (2014). Diabetes mellitus increases risk for colorectal adenomas in younger patients. World J Gastroenterol, 20, 6946-52. DOI |
31 | Warren R, Yuan H, Matli M, Ferrara N, Donner D (1996). Induction of vascular endothelial growth factor by insulinlike growth factor 1 in colorectal carcinoma. J Biol Chem, 271, 29483-8. DOI |
32 | Williams A, Collard T, Perks C, et al (2000). Increased p53- dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res, 60, 22-7. |
33 | Yun K, Chang Y, Jung H, et al (2013). Impact of body mass index on the risk of colorectal adenoma in a metabolically healthy population. Cancer Res, 73, 4020-7. DOI |
34 | Zaafar D, Zaitone S & Moustafa Y (2014). Role of metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation. PLoS One, 9, 100562. DOI |
35 | Zaninotto P, Pierce M, Breeze E, De Oliveira C, Kumari M (2010). BMI and waist circumference as predictors of wellbeing in older adults: findings from the english longitudinal study of ageing. Obesity, 18, 1981-7. DOI |
36 | Zhang P, Li H, Tan X, Chen L, Wang S (2013a). Association of metformin use with cancer incidence and mortality: a metaanalysis. Cancer Epidemiol, 37, 207-18. DOI |
37 | Zhang Y, Guan M, Zheng Z, et al (2013b). Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS |
38 | Mahmood K, Naeem M & Rahimnajjad N (2013). Metformin: the hidden chronicles of a magic drug. Eur J Intern Med, 24, 20-6. DOI |
39 | Lega I, Shah P, Margel D, et al (2014). The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev, 23, 1974-84. DOI |
40 | Li W, Wang Q, Liu X, et al (2015). Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res, 8, 139-48. DOI |
41 | Mei Z, Zhang Z, Liu C, et al (2014). Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One, 9, 91818. DOI |
42 | Mulholland H, Murray L, Cardwell C & Cantwell M (2009). Glycemic index, glycemic load, and risk of digestive tract neoplasms: a systematic review and meta-analysis. Am J Clin Nutr, 89, 568-76. DOI |
43 | Na S & Myung S (2012). [Obesity and colorectal cancer]. Korean J Gastroenterol, 59, 16-26. DOI |
44 | Ogden C, Carroll M, Curtin L, et al (2006). Prevalence of overweight and obesity in the United States, 1999-2004. JAMA, 295, 1549-55. DOI |
45 | Pais R, Silaghi H, Silaghi A, Rusu M & Dumitrascu D (2009). Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol, 15, 5141-8. DOI |
46 | Rampal S, Yang MH, Sung J, et al (2014). Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterol, 147, 78-87. DOI |
47 | Renehan A, Roberts D, Dive C (2008). Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem, 114, 71-83. DOI |